Last reviewed · How we verify
NCT03792932
Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer
NA trial testing Laparoscopic distal pancreatectomy in Pancreatic Cancer in 306 participants. Status unknown.
31 January 2023
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 306 |
| Start date | 2 February 2019 |
| Primary completion | 31 January 2023 |
| Estimated completion | 31 January 2023 |
| Sites | 11 locations across China |
Drugs / interventions tested
- Laparoscopic distal pancreatectomy
- Open distal pancreatectomy
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Surgery — all drugs for Surgery →
- Laparoscopy — all drugs for Laparoscopy →
Sponsor
Fudan University
Who can join
Adults 19 to 80, any sex, with Pancreatic Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Open distal pancreatectomy (ODP) has been commonly employed for the treatment of a variety of cancers in body and tail of pancreas. Although many general surgical procedures have been increasingly performed laparoscopically or with laparoscopic assistance, until the current decade, laparoscopic pancreatic surgery had not been performed for its complicated anatomy. But laparoscopic distal pancreatectomy (LDP) has been widely accepted as a standard treatment for body and tail pancreatic cancer because there is no anastomosis in it, and LDP has gradually become the first choice for these cancers in clinical work. Although there are several studies about the comparison between LDP and ODP, most are retrospective and there is no agreement in surgical margin, lymph node numbers and prognosis to identify the oncological differences between the two surgical approaches. The investigators' pilot study showed that patients with body and tail pancreatic cancer underwent LDP had a better prognosis compared with the ones undergoing ODP, with no statistics differences in postoperative complications and mortality. This perspective RCT study is performed to confirm whether LDP would improve the prognosis for patients with body and tail pancreatic cancer compared with ODP.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Landmark Series: Minimally Invasive Pancreatic Resection.
van Hilst J, de Graaf N, Abu Hilal M, Besselink MG. · · 2021 · cited 35× · PMID 33341916 · DOI 10.1245/s10434-020-09335-3 -
Minimally invasive versus open pancreatic surgery: meta-analysis of randomized clinical trials.
Pfister M, Probst P, Müller PC, Antony P, et al · · 2023 · cited 25× · PMID 36967469 · DOI 10.1093/bjsopen/zrad007 -
Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial.
van Hilst J, Korrel M, Lof S, de Rooij T, et al · · 2021 · cited 25× · PMID 34503548 · DOI 10.1186/s13063-021-05506-z -
Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Korrel M, Lof S, van Hilst J, Alseidi A, et al · · 2021 · cited 13× · PMID 32583198 · DOI 10.1245/s10434-020-08658-5 -
Protocol for a randomised controlled trial to compare postoperative complications between minimally invasive and open DIStal PAnCreaTectomy (DISPACT-2 trial).
Probst P, Schuh F, Dörr-Harim C, Sander A, et al · · 2021 · cited 7× · PMID 33619204 · DOI 10.1136/bmjopen-2020-047867 -
Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Trial.
Liu C, Cheng H, Wang M, Cai Y, et al · · 2025 · cited 1× · PMID 39996303 · DOI 10.1097/sla.0000000000006681 -
Minimally Invasive versus Open Distal Pancreatectomy in the 2020s: Recent Institutional Experience and a Narrative Review of Current Evidence.
Rehman S, Patel I, Bartlett D, Mirza D. · · 2023 · cited 1× · PMID 37892716 · DOI 10.3390/jcm12206578
Verify or expand the search:
- PubMed search for NCT03792932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Laparoscopic distal pancreatectomy
Trials testing the same drug.
- NCT03957135 — Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Cancer: a Multicenter Randomized Controlled Trial · NA · unknown
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03792932 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 22 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03792932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing